Vanda Pharmaceuticals (VNDA) Operating Expenses (2010 - 2026)

Vanda Pharmaceuticals' Operating Expenses history runs 17 years deep, the most recent figure standing at $101.9 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 11.94% year-over-year to $101.9 million; the TTM figure through Mar 2026 stood at $378.1 million (up 38.11% YoY), while the FY2025 annual figure was $367.3 million, up 53.39% from the prior year.
• Operating Expenses came in at $101.9 million for Q1 2026 at Vanda Pharmaceuticals, up from $97.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $101.9 million in Q1 2026 to a low of $44.8 million in Q3 2023.
• A 5-year average of $68.4 million and a median of $60.9 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses retreated 27.03% in 2023 and surged 60.62% in 2025, its largest moves.
• Vanda Pharmaceuticals' Operating Expenses stood at $57.9 million in 2022, then slipped by 9.49% to $52.4 million in 2023, then grew by 21.2% to $63.5 million in 2024, then soared by 53.74% to $97.6 million in 2025, then climbed by 4.48% to $101.9 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $101.9 million, $97.6 million, and $87.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison